bluuebunny/crossref_metadata_2025_split huggingface dataset:
Synthesis and Cytotoxicity of Platinum(II) Complexes of a Physiologically Active Carrier Histamine
Authors: Chen Xi‐Zhu , Ye Qing‐Song , Lou Li‐Guang , Xie Ming‐Jin , Liu Wei‐Ping , Yu Yao , Hou Shu‐Qian 
Published: January 2008

AbstractA series of novel platinum(II) complexes involving a physiologically active carrier histamine as the carrier,cis‐[Pt(histamine)X2] (X2= 2Cl–, oxalate, malonate, 1,1‐cyclobutanedicarboxylate (CBDCA), 3‐hydroxy‐1,1‐cyclobutanedicarboxylate (HO‐CBDCA)), have been synthesized and characterized by elemental analysis and spectroscopic data along with X‐ray crystal structure for a representative complexcis‐[Pt(histamine)Cl2]. The cytotoxicity of the complexes has also been assessed in the human cancer cell lines A549/ATCC, HT‐29, and LNcap. One complex,cis‐[Pt(histamine)Cl2], is more active than carboplatin against both the sensitive and resistant cells.
A conserved stable core structure in the passenger domain β‐helix of autotransporter virulence proteins
Authors: Renn Jonathan P. , Clark Patricia L. 
Published: January 2008

AbstractIn Gram‐negative bacteria, a wide variety of virulence factors are secreted via the autotransporter (AT) pathway. Intriguingly, there is no significant concentration of ATP in the periplasm, nor a proton gradient across the OM, so the energetic origin of efficient secretion of AT proteins is unknown. More than 97% of AT proteins are predicted to contain right‐handed parallel β‐helical structure, and the three crystal structures available for AT passenger domains each contain a long right‐handed parallel β‐helix. Previous studies have shown that pertactin, an AT from Bordetella pertussis, exhibits three‐state folding and has a C‐terminal stable core structure. Here, we show that Pet, an unrelated AT from Escherichia coli, also exhibits three‐state unfolding and also has a stable core structure. Deletion mutants, mass spectrometry, and N‐terminal sequencing demonstrate that the Pet stable core is also located near the C‐terminus of the passenger domain. Moreover, sequence analysis suggests that three‐state folding and a C‐terminal stable core structure could be important general features of the biogenesis of AT proteins in vivo. © 2008 Wiley Periodicals, Inc. Biopolymers 89: 420–427, 2008.This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com
Determination of caudatin‐2,6‐dideoxy‐3‐O‐methy‐β‐d‐cymaropyranoside in rat plasma using liquid chromatography–tandem mass spectrometry
Authors: Peng Yunru , Li Youbin , Wang Dawei , Liu Xiaodong , Zhang Jianfeng , Qian Shihui , Duan Jinao 
Published: January 2008

AbstractA selective, sensitive and rapid liquid chromatography–tandem mass spectrometry method has been developed for the determination of caudatin‐2,6‐dideoxy‐3‐O‐methy‐β‐d‐cymaropyranoside (CDMC) in rat plasma. This method involves a plasma clean‐up step using liquid–liquid extraction, followed by LC separation and positive electrospray ionization mass spectrometry detection (LC/ESI‐MS/MS). Chromatographic separation of the analytes was achieved using a C18 column with a mobile phase of acetonitrile and water (70:30, v/v) at a flow rate of 1.0 mL/min. Low energy collision tandem mass spectrometric analysis (CID‐MS/MS) using the multiple reaction monitoring (MRM) mode was used for analyte quantification. For the MRM analysis of CDMC, the following transition at m/z 658.4 → 529.6 derived from the protonated molecule [M + Na]+. A calibration curve was linear in the 5–500 ng/mL range for CDMC, and the limit of detection was 5 ng/mL. The inter‐ and intra‐day precisions (RSD) were ≤8.5 and ≤9.1%, respectively. The accuracy (RE) was ± 10.9%. The novel developed LC/ESI‐MS/MS method was successfully applied to pharmacokinetic studies of CDMC after oral administration to rats. The total chromatographic run time of this method was 5.0 min per sample, allowing for analysis of a large number of samples per batch. Copyright © 2008 John Wiley & Sons, Ltd.
The posterior inferior cerebellar artery and its branches in relation to the cerebellomedullary fissure
Authors: Ucerler H. , Saylam C. , Cagli S. , Orhan M. , Zileli M. 
Published: January 2008

AbstractThe conventional approach to the fourth ventricle is by splitting the vermis on the suboccipital surface of the cerebellum. By a unilateral transcerebellomedullary fissure approach, it is possible to provide sufficient operative space from cerebral aqueduct to obex without splitting the vermis. This approach needs meticulous dissection of the cerebellomedullary fissure and preservation of the posterior inferior cerebellar artery (PICA) and its branches. The tonsillomedullary and telovelotonsillar segments of the PICA are the most important vessels encountered in the transcerebellomedullary fissure approach. The PICA was examined under a surgical microscope in a total of 40 specimens by perfusing with a mixture of 10% Indian ink and gelatin. The passing of the tonsillomedullary segment of the PICA through the cerebellomedullary fissure was observed superior to the tonsil in 5%, at the level of the upper pole of the tonsil in 17.5%, at the middle of the tonsil in 37.5% and at the level of the lower pole of the tonsil in 37.5% specimens. When the PICA arose from the lateral medullary (LM) segment of the vertebral artery (VA), a caudal loop was present in 90%, when the PICA originated from the premedullary segment of the VA, the loop was present in 87.5% specimens. When the PICA arose from the basilar artery (BA), the loop was absent, and the tonsillomedullary segment of the PICA showed a straight course (100%). A thorough understanding of the relationship of the branches of the PICA to the cerebellar tonsils are prerequisites for surgery in and around the fourth ventricle. Clin. Anat. 21:119–126, 2008. © 2008 Wiley‐Liss, Inc.
Indoloquinolizidine Derivatives as Novel and Potent Apoptosis Inducers and Cell‐Cycle Blockers
Authors: Wehner Frank , Nören‐Müller Andrea , Müller Oliver , Reis‐Corrêa Ivan , Giannis Athanassios , Waldmann Herbert 
Published: January 2008

AbstractA collection of approximately 11 000 natural‐product derived and inspired compounds was screened for potential apoptosis inducers in the human tumour cell lines HepG2 (liver), HeLa (cervix) and MCF‐7 (breast) by means of MTT and ATP‐luminescence assays, automated cell counting, caspase 3/7 assay as well as by fluorescence activated cell sorting (FACS) analysis. A group of seven indoloquinolizidine derivatives was identified that exhibited IC50 values for cell proliferation as low as 2 μmol L−1, with no major necrosis of cells detectable. At the same time, an increase in the rate of apoptosis of up to 600 % relative to the reference level was observed. FACS analysis indicated that these effects are related to an arrest of cells in the G2M phase of the cell cycle.
New Synthesis of 2‐Heteroarylperfluoropropionic Acids Derivatives by Reaction of Azine N‐Oxides with Hexafluoropropene
Authors: Loska Rafał , Mąkosza Mieczysław 
Published: January 2008

AbstractHexafluoropropene reacts with aromatic azine N‐oxides under mild conditions to produce fluorides of 2‐heteroarylperfluoropropionic acids. The reaction proceeds as 1,3‐dipolar cycloaddition followed by spontaneous scission of the NO bond in the isoxazolidine ring and elimination of HF. When the reaction is carried out in the presence of alcohols or N‐alkyl anilines, the in situ formed acyl fluorides give the corresponding esters and amides. They can be also treated separately with nucleophiles to produce the respective acylation products, whereas their hydrolysis leads to unstable carboxylic acids that undergo spontaneous decarboxylation to 1‐aryl‐1,2,2,2‐tetrafluoroethanes. This new reaction provides a simple and general method of synthesizing 2‐heteroarylperfluoropropionic acid derivatives that were previously unknown and unavailable.
Direct Thermal Decomposition of Metal Nitrates in Octadecylamine to Metal Oxide Nanocrystals
Authors: Wang Ding‐Sheng , Xie Ting , Peng Qing , Zhang Shao‐Yan , Chen Jun , Li Ya‐Dong 
Published: January 2008

AbstractWe have developed a method for the synthesis of metal oxide nanocrystals with controllable shape and size, which is based on the direct thermal decomposition of metal nitrates in octadecylamine. Mn3O4 nanoparticles and nanorods with different lengths were synthesized by using manganese nitrate as the decomposition material. Other metal oxide nanocrystals such as NiO, ZnO, CeO2, CoO, and Co3O4 were also prepared by this method. These nanocrystals were then assembled into 3D colloidal spheres by a surfactant‐assisted self‐assembly process. Subsequently, calcination was carried out to remove the surfactants to obtain mesoporous metal oxides, which show large pores, good crystallization, thermally stable pore mesostructures, and potential applications in various fields, especially in catalysis and lithium‐ion batteries.
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium‐90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non‐Hodgkin lymphoma
Authors: Zinzani Pier Luigi , Tani Monica , Fanti Stefano , Stefoni Vittorio , Musuraca Gerardo , Vitolo Umberto , Perrotti Alessio , Fina Mariapaola , Derenzini Enrico , Baccarani Michele 
Published: January 2008

AbstractBACKGROUNDA prospective, single‐arm, open‐label, nonrandomized Phase 2 study of combined fludarabine and mitoxantrone (FM) plus radioimmunotherapy was conducted to evaluate efficacy and safety in patients with untreated, indolent, nonfollicular non‐Hodgkin lymphoma (NHL).METHODSBetween February 2005 and June 2006, at their institute, the authors treated 26 eligible patients with previously untreated, indolent, nonfollicular NHL (10 marginal zone lymphomas, 8 lymphoplasmacytic lymphomas, and 8 small lymphocytic lymphomas) using a novel regimen that consisted of 6 cycles of FM chemotherapy followed 6 to 10 weeks later by yttrium‐90 (90Y) ibritumomab tiuxetan.RESULTSAfter FM chemotherapy, the overall response rate was 80.5% and included a 50% complete remission (CR) rate (13 patients) and a 30.5% partial remission (PR) rate (8 patients). Of the 20 patients (13 with CR and 7 with PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent 90Y ibritumomab tiuxetan, 100% obtained a CR at the end of the entire treatment regimen. At a median follow‐up of 20 months, the estimated 3‐year progression‐free survival rate was 89.5%, and the estimated 3‐year overall survival rate was 100%. The 90Y ibritumomab tiuxetan toxicity included grade ≥3 hematologic toxicity in 16 of 20 patients; the most common grade ≥3 toxicities were neutropenia (11 patients) and thrombocytopenia (16 patients) (adverse events were graded according to the World Health Organization criteria for toxicity). Transfusions of erythrocytes and/or platelets were given to 5 patients.CONCLUSIONSThe current study established the feasibility, tolerability, and efficacy of the FM plus 90Y ibritumomab tiuxetan regimen for the treatment of patients with untreated, indolent, nonfollicular NHL. Cancer 2008. © 2008 American Cancer Society.
Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population
Authors: Dobie Sharon A. , Warren Joan L. , Matthews Barbara , Schwartz David , Baldwin Laura‐Mae , Billingsley Kevin 
Published: January 2008

AbstractBACKGROUNDThis study examined elderly stage II and III rectal cancer patients' adjuvant chemoradiation therapy adherence, trends in adherence over time, and the relation of levels of adherence to mortality.METHODSThe authors studied 2886 stage II and III rectal cancer patients who had surgical resection and who appeared in 1992–1999 linked SEER‐Medicare claims data. The authors compared measures of adjuvant radiation and chemotherapy receipt and completion between stage II and III patients. Adjusted risk of cancer‐related 5‐year mortality was calculated by multivariate logistic regression for different levels of chemoradiation adherence among stage II and III patients.RESULTSOf the 2886 patients, 45.4% received both adjuvant radiation and chemotherapy. Stage III patients were more likely to receive chemoradiation than stage II patients. The receipt of chemoradiation by stage II patients increased significantly from 1992 to 1999. Stage III patients were more likely to complete radiation therapy (96.6%), chemotherapy (68.2%), and both modalities (67.5%) than stage II patients (91.5%, 49.8%, 47.6%, respectively). Only a complete course of both radiation and chemotherapy for both stage II (relative risk [RR] 0.74; 95% CI, 0.54, 0.97) and III (RR 0.80; 95% CI, 0.65, 0.96) decreased the adjusted 5‐year cancer mortality risk compared with counterparts with no adjuvant therapy.CONCLUSIONSEven though stage II rectal cancer patients were less likely than stage III patients to receive and complete adjuvant chemoradiation, both patient groups in the general population had lower cancer‐related mortality if they completed chemoradiation. These patients deserve support and encouragement to complete treatment. Cancer 2008. © 2008 American Cancer Society.
Nonplatinum‐based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma
Authors: Kiyota Naomi , Tahara Makoto , Fujii Satoshi , Kawashima Mitsuhiko , Ogino Takashi , Minami Hironobu , Hayashi Ryuichi , Ohtsu Atsushi 
Published: January 2008

AbstractBACKGROUNDThe efficacy and safety of chemotherapy with irinotecan plus docetaxel were retrospectively evaluated for olfactory neuroblastoma.METHODSTwelve patients with histologically proven advanced or metastatic olfactory neuroblastoma were treated with chemotherapy with irinotecan plus docetaxel at the study institution between 2001 and 2005. Of these, 7 patients with locoregional disease and no prior radiotherapy received irinotecan plus docetaxel followed by definitive radiotherapy, 1 with photon radiotherapy and 6 with proton radiotherapy, whereas 3 patients with distant metastases and 2 with locoregional disease who had received prior radiotherapy received irinotecan plus docetaxel only.RESULTSThe most common toxicities of ≥grade 3 among the 12 patients receiving irinotecan plus docetaxel were leukopenia (33%), neutropenia (50%), febrile neutropenia (8%), and diarrhea (25%), all of which were manageable. Partial response was achieved in 3 patients, giving an overall response rate of 25%. The response rate was higher in patients aged <50 years (3 of 4 patients) compared with those aged >50 years (0 of 8 patients) (P = .018). With a median follow‐up period of 22.2 months, the median progression‐free survival and overall survival were 13.6 months and 36.6 months, respectively. Of the 7 patients with locoregional disease also receiving definitive radiotherapy, the 2‐year survival rate was 100% and 6 patients were alive at the time of last follow‐up.CONCLUSIONSChemotherapy for olfactory neuroblastoma with irinotecan plus docetaxel is safe and manageable. Patients aged <50 years may be sensitive to chemotherapy. Induction chemotherapy followed by definitive radiotherapy may represent a promising option for patients with locally advanced olfactory neuroblastoma. Cancer 2008. © 2008 American Cancer Society.
Is mode of breast cancer detection associated with cancer treatment in the United States?
Authors: Yabroff K. Robin , Harlan Linda C. , Clegg Limin X. , Ballard‐Barbash Rachel , Stevens Jennifer , Weaver Donald L. 
Published: January 2008

AbstractBACKGROUNDThe prognosis for women who have breast cancer detected by mammography is more favorable than that for women who have breast cancer detected by other methods, even after controlling for tumor characteristics. In the current study, the authors explored whether detection by mammography was associated with greater use of guideline‐consistent breast cancer treatment among patients with recently diagnosed breast cancer in the United States.METHODSThe authors evaluated the association between mode of breast cancer detection (mammography vs other) and use of guideline‐consistent treatment in 1006 women aged ≥40 years who were diagnosed in 2000. These patients were sampled from the Surveillance, Epidemiology, and End Results Program as part of the Patterns of Care studies. The analyses controlled for the potential confounders of clinical, demographic, and health system characteristics in multivariate logistic regression models.RESULTSBreast cancer patients who were diagnosed by mammography were more likely to be aged ≥55 years, to have lower stage disease, and to be treated in larger hospitals than patients who were diagnosed by other methods (P < .05). Women whose breast cancer was diagnosed by a method other than mammography were more likely to receive guideline‐consistent treatment than women who were diagnosed by mammography in unadjusted (odds ratio, 1.39; 95% confidence interval, 1.07–1.80) and multivariate analyses (odds ratio, 1.43; 95% confidence interval, 1.05–1.95).CONCLUSIONSThe current results indicated that women who had breast cancer detected by methods other than mammography were slightly more likely to receive guideline‐consistent therapy than women who had breast cancer detected by mammography. Future research exploring mode of detection, guideline‐consistent treatment, and survival among patients with recently diagnosed breast cancer may inform understanding of factors associated with breast cancer prognosis. Cancer 2008. Published 2008 by the American Cancer Society.
Determinants of breast cancer knowledge among newly diagnosed, low‐income, medically underserved women with breast cancer
Authors: Chen Judy Y. , Diamant Allison L. , Thind Amardeep , Maly Rose C. 
Published: January 2008

AbstractBACKGROUNDAmong women with breast cancer (BC), greater BC knowledge has been associated with greater participation in treatment decision‐making, patient satisfaction, and survival. The objective of this study was to identify modifiable determinants associated with BC knowledge.METHODSData were collected from a telephone survey of medically underserved women with BC in California (n = 909). The dependent variable for analysis was BC knowledge. The modifiable determinants that were assessed included 1) physician‐patient discussion of BC topics, 2) receipt of written BC‐related material, 3) self‐efficacy in interacting with physicians, 4) physician emotional support, 5) discussions with a BC survivor, and 6) office visit support by relatives/friends. Multivariate linear regression was used to examine the effect of those determinants on BC knowledge while controlling for socioeconomic factors, clinical characteristics, and treatment received.RESULTSThe average knowledge score was 6.9 (standard deviation, 2.3; range, 0–10). In multivariate analyses among women with less physician emotional support, those with the greatest self‐efficacy had higher knowledge scores than those with the least self‐efficacy (8.2 vs 5.4; P < .001). For women with low self‐efficacy, those with more physician emotional support had higher knowledge scores than those with less physician emotional support when the analysis was controlled for confounding factors (6.3 vs 5.4; P < .001); physician information‐giving had no effect on BC knowledge.CONCLUSIONSThe study findings suggested significant associations of patient self‐efficacy and physician emotional support with BC knowledge; physician emotional support appeared to be more important than physician informational support. Further research will be needed to investigate whether interventions that target these 2 domains may be effective in increasing BC knowledge in disadvantaged populations. Cancer 2008. © 2008 American Cancer Society.
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first‐line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Authors: Hainsworth John D. , Vazquez Elizabeth R. , Spigel David R. , Raefsky Eric , Bearden James D. , Saez Ruben A. , Greco F. Anthony 
Published: January 2008

AbstractBACKGROUNDThe purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).METHODSIn a nonrandomized phase 2 trial, 41 patients who had previously untreated CLL or SLL and required treatment received 4 cycles of the fludarabine and rituximab combination followed 5 weeks later by 4 weeks (12 doses) of intravenous alemtuzumab therapy. The response to treatment was evaluated after completion of treatment with fludarabine and rituximab, and again after the completion of alemtuzumab consolidation.RESULTSInitial treatment with the combination of fludarabine and rituximab was well tolerated, and produced a 71% overall response rate (13% complete response). Thirty‐four patients began treatment with intravenous alemtuzumab, but this drug was relatively poorly tolerated when given at a short interval after fludarabine and rituximab, and only 20 patients (49% of total) were able to complete the prescribed course. Five patients had an improvement in their response with alemtuzumab; the final complete response rate was 21%. The median progression‐free survival for the entire group was 42 months. Toxicity with alemtuzumab included infusion‐related toxicity, myelosuppression, and opportunistic infections.CONCLUSIONSThe intravenous schedule of alemtuzumab employed in the trial was relatively poorly tolerated in this community‐based trial. The relatively low complete response rates after treatment with the combination of fludarabine and rituximab and after the completion of treatment suggest that these abbreviated courses may compromise efficacy. The generalized use of alemtuzumab as consolidation therapy cannot yet be recommended for community practice. However, optimization of the route of administration, duration of treatment, and interval after completion of induction therapy may improve efficacy, and further investigation is ongoing. Cancer 2008. © 2008 American Cancer Society.
Generation of Nanopores Down to 10 nm for Use in Deep‐Nulling Interferometry
Authors: Wehling Axel , Pohl Wiebke H. , Gerke Birgit , Kipp Stephan , Walla Peter J. 
Published: January 2008

AbstractScanning electron microscope images show that it is easy to generate nanopores on polycarbonate membranes with well‐defined pore diameters by ion‐track perforation and subsequent magnetron sputtering with metal. The size reduction of the nanopores during sputtering with gold is a linear function of time. Images of different angles and from the bottom side of the membrane show that the channels are the smallest very close to the surface of the metal layer, have a conelike shape, and reach about half as much into the polymer membranes as the metal‐layer thickness. This topographical pore shape is ideal for use as optically coherent near‐field sources in deep‐nulling microscopy. We present the first results of significantly improved nulling stabilization in the presence (<2 nm optical pathway difference) and the absence (<0.6 nm optical pathway difference) of the nanoapertures in the focal region of a deep‐nulling microscope.